Investing.com España Market update
News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 1–36
- Matches
- 619
- Sources here
- 14
- Companies here
- 12
Active search
619 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
ETFs Investing in Paramount Skydance Corporation Class B Stocks
This article lists various Exchange Traded Funds (ETFs) that hold Paramount Skydance Corporation Class B stocks, providing details such as market value, weight, issuer, management style, focus, expense ratio, and assets under management (AUM) for each ETF. These funds offer investors a way to …
Skye Bioscience to acquire Redx Pharma in $125M deal By Investing.com
Skye Bioscience announced its definitive agreement to acquire Redx Pharma through a scheme of arrangement under U.K. law for an approximate $125 million deal. The merged entity will be known as Fibrx Therapeutics Inc., trading on Nasdaq, and will be led by Redx's current …
The Hulk Fame Mark Ruffalo Slams Jamie Dimon Over Paramount-Warner Merger, Blames Ellison-Trump 'Cozy Relationship' for Deal Not Being Stopped
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On Wednesday, Mark Ruffalo criticized Paramount Skydance Corp CEO David Ellison's proposed Warner Bros. Discovery, Inc. takeover, throwing his support behind California Attorney General Rob Bonta as …
Sharemaestro market context Price below Trend Line 52 weeks -42.0% · Next-week setup negative 31.3%Paramount clears regulatory hurdles for Warner Bros. Discovery deal
Investing.com -- Paramount Skydance said on Friday it had secured all regulatory clearances required under its merger agreement to acquire Warner Bros. Discovery, removing the final regulatory obstacle to the proposed combination after an eight-month review spanning 68 countries. The latest clearance came from …
Sharemaestro market context Price below Trend Line 52 weeks -42.0% · Next-week setup negative 31.3%Alyeska group discloses 1.16% SKYX Platforms (SKYX) ownership in 13G/A
Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh have jointly reported a beneficial ownership of 1,555,509 shares of SKYX Platforms Corp. common stock, which represents 1.16% of the class. This updated Schedule 13G/A filing indicates that the group now owns 5% …
PARAMOUNT SKYDANCE SATISFIES ALL REGULATORY CONDITIONS UNDER THE MERGER AGREEMENT TO CLOSE WARNER BROS. DISCOVERY ACQUISITION, SECURING CLEARANCES IN NEARLY 70 COUNTRIES WORLDWIDE
LOS ANGELES and NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Paramount Skydance Corporation (NASDAQ: PSKY) ("Paramount") has satisfied all regulatory clearances required under the merger agreement to close its proposed acquisition of Warner Bros. Discovery, Inc. (NASDAQ: WBD) ("WBD"). The eight-month review process has …
Sharemaestro market context Price below Trend Line 52 weeks -42.0% · Next-week setup negative 31.3%American Century group discloses 5.7% SkyWest (SKYW) ownership for advised accounts
American Century entities and the Stowers Institute have reported passive ownership stakes in SkyWest, Inc. common stock. As of June 30, 2026, American Century ETF Trust held 2,158,046 shares (5.4%), while American Century Investment Management, Inc., American Century Companies, Inc., and the Stowers Institute …
Paramount and Warner Bros. Stocks Are Rallying. What That Says About the Takeover.
The odds of the Hollywood megamerger happening appear to be improving, judging by recent stock moves. Continue Reading
Sharemaestro market context Price below Trend Line 52 weeks -42.0% · Next-week setup negative 31.3%Form 8K Skye Bioscience Inc For: 14 August By Investing.com
This article reports that Skye Bioscience Inc. filed a Form 8K on August 14. The filing is a standard disclosure document used by public companies to announce major events that shareholders should know about. The article provides no further details on the content of …
Skyward Specialty (SKWD): T. Rowe Price Associates reports 6% ownership stake
T. Rowe Price Associates, Inc. has reported a beneficial ownership of 6.0% in Skyward Specialty Insurance common stock, totaling 2,441,073 shares as of June 30, 2026. The firm holds sole voting power over 2,440,261 shares and sole dispositive power over all 2,441,073 shares. This …
Skye Bioscience to Acquire Redx; Secures $67.9M Financing and $22M Equity Line
Skye Bioscience is set to acquire Redx through a UK court-sanctioned scheme of arrangement, backed by a significant financing package. The deal includes a $67.9 million equity financing (potentially rising to $72.9 million), a $22.0 million equity line, and a $5.0 million warrant with …
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
Skye Bioscience and Redx Pharma have announced a definitive transaction agreement, forming a combined company named Fibrx Therapeutics, which will focus on developing novel small molecule medicines for fibrotic diseases. This merger is supported by approximately $125 million in financings, including a PIPE financing …
FY2029 EPS Estimates for SKYX Platforms Lowered by Analyst
Litchfield Hills Research has lowered its FY2029 EPS estimate for SKYX Platforms (NASDAQ:SKYX) to $0.13 from $0.14, while projecting FY2030 EPS at $0.16. Despite missing quarterly EPS expectations by $0.01, SKYX Platforms exceeded revenue estimates and maintains a "Moderate Buy" consensus rating with an …
Skye Bioscience (NASDAQ: SKYE) exits obesity trial, pursues Redx merger and $100M+ funding
Skye Bioscience is discontinuing its nimacimab obesity program and pursuing a merger with Redx Pharma to form Fibrx Therapeutics, Inc. This strategic shift addresses significant financial strains, as evidenced by a $23.3 million net loss and a substantial doubt about its ability to continue …
Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary
Skye Bioscience, Inc. reported its 2026 quarterly results, showing revenue of $178.2K and a net loss of ($10.79M), leading to a diluted loss per share of ($0.27), which is an improvement over the prior year. The company also announced the termination of its CBeyond …
Traders Bet on Growing Chance of Paramount-Warner Deal Closing
(Bloomberg) -- Traders are growing more confident that the $110 billion merger between Paramount Skydance Corp. and Warner Bros. Discovery Inc. will move forward despite an ongoing legal battle with US states. Most Read from Bloomberg Selena Gomez Accused of Fraud by Mental-Health Startup …
Sharemaestro market context Price below Trend Line 52 weeks -42.0% · Next-week setup negative 31.3%Zacks Industry Outlook Highlights The Berkeley Group and Sky Harbour
For Immediate Release Chicago, IL – August 14, 2026 – Today, Zacks Equity Research discusses The Berkeley Group Holdings plc BKGFY and Sky Harbour Group Corporation SKYH. Industry: Real Estate – Development Link to article:https://www.zacks.com/commentary/2974557/2-real-estate-development-stocks-to-consider-as-fundamentals-rebound 2 Real Estate Development Stocks to Consider as Fundamentals …
SKYX Platforms (SKYX) Q2 2026 Earnings Call: Revenue Reaches $25.3 Million
SKYX Platforms reported record Q2 2026 revenue of $25.3 million, a 14% sequential and 10% year-over-year increase, marking its tenth consecutive quarter of top-line growth. Gross profit reached $7.3 million, and operating cash usage improved by 39% sequentially to $3.7 million. The company aims …
Paramount just offered up its crown jewel
When regulators threaten to block a merger, the company on the other side usually offers something replaceable. A distribution deal. A regional station. A slice of market share nobody will miss. Paramount Skydance just put its most recognizable news brand on the table instead. …
Sharemaestro market context Price below Trend Line 52 weeks -42.0% · Next-week setup negative 31.3%Boston Omaha Corp, 10% owner, sells $3.6m of Sky Harbour Group stock
Boston Omaha Corp, a 10% owner of Sky Harbour Group Corp (SKYH), sold 360,000 shares of Class A common stock for $3.6 million on August 11, 2026. This sale comes as InvestingPro analysis suggests SKYH is overvalued, despite the stock showing a 25% return …
Boston Omaha Corp (SKYH) reports 360,000-share sale and large remaining stake
Boston Omaha Corporation, a major shareholder in Sky Harbour Group Corp (SKYH), sold 360,000 shares of Class A common stock at $10.00 per share on August 11, 2026. Following this transaction, Boston Omaha still directly holds 8,306,163 shares and indirectly holds an additional 2,673,831 …
Champion Homes (SKY) Stock Looks Overvalued After A 63% Five Year Gain
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Champion Homes stock has delivered a 63.4% return over the past five years, yet its valuation signals are mixed, with a fairly valued Discounted Cash …
Sky Harbour announces $40 million equity financing deal
Sky Harbour Group (SKYH) has completed a registered direct offering, securing $40 million in gross proceeds through the sale of 4,000,000 Class A common shares at $10.00 each. This financing, along with concurrent secondary sales by Boston Omaha Corporation, aims to strengthen the company's …
Invesco Ltd. (SKWD holder) reports 5.0% Skyward Specialty ownership stake
Invesco Ltd. has disclosed a 5.0% ownership stake in Skyward Specialty Insurance Group Inc. (SKWD), holding 2,037,771 shares. The investment firm reported sole voting power over 1,874,922 shares and sole dispositive power over all 2,037,771 shares. This passive investment is held for clients of …